Payment overview · 2025
General Payments
$76.65
3 reported records · 2 companies
Healthcare provider profile · identity verified
Robert Drvol, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Adolescent Medicine · OMAHA, NE · NPI 1508916594
Verified facts
What the public records show
CMS Open Payments records show Robert Drvol, M.D. received $76.65 in general payments during 2025 across 3 reported records.
Inspire Medical Systems, Inc. accounted for 71.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $55.04 | 71.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.61 | 28.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.65 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $55.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 82 |
| Omeprazole | Omeprazole | 379 | 95 |
| Lisinopril | Lisinopril | 347 | 102 |
| Gabapentin | Gabapentin | 339 | 87 |
| Meloxicam | Meloxicam | 264 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 66 |
| Losartan Potassium | Losartan Potassium | 235 | 63 |
| Potassium Chloride | Potassium Chloride | 231 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 54 |
| Sertraline Hcl | Sertraline Hcl | 210 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 54 |
| Eliquis | Apixaban | 196 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 192 | 45 |
| Alendronate Sodium | Alendronate Sodium | 188 | 49 |
| Metformin Hcl | Metformin Hcl | 169 | 45 |
| Simvastatin | Simvastatin | 162 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 33 |
| Furosemide | Furosemide | 145 | 43 |
| Memantine Hcl | Memantine Hcl | 141 | 19 |
| Mounjaro | Tirzepatide | 140 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 36 |
| Famotidine | Famotidine | 128 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 127 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 30 |
| Trazodone Hcl | Trazodone Hcl | 120 | 34 |
| Bupropion Xl | Bupropion Hcl | 113 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 48 |
| Doxazosin Mesylate | Doxazosin Mesylate | 104 | 25 |
| Ezetimibe | Ezetimibe | 103 | 27 |
| Chlorthalidone | Chlorthalidone | 95 | 26 |
| Allopurinol | Allopurinol | 92 | 25 |
| Ozempic | Semaglutide | 92 | 19 |
| Donepezil Hcl | Donepezil Hcl | 91 | 19 |
| Carvedilol | Carvedilol | 90 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 13 |
| Glimepiride | Glimepiride | 83 | 24 |
| Alprazolam | Alprazolam | 82 | 22 |
| Montelukast Sodium | Montelukast Sodium | 82 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 78 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 22 |
| Atenolol | Atenolol | 72 | 18 |
| Risperidone | Risperidone | 72 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 18 |
| Metformin Hcl Er | Metformin Hcl | 70 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 25 |
| Mirtazapine | Mirtazapine | 64 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | suppressed |
| Spironolactone | Spironolactone | 58 | 12 |
| Clonidine Hcl | Clonidine Hcl | 57 | suppressed |
| Baclofen | Baclofen | 56 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 15 |
| Jardiance | Empagliflozin | 55 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 12 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 29 |
| Colestipol Hcl | Colestipol Hcl | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Nitroglycerin | Nitroglycerin | 42 | 32 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Finasteride | Finasteride | 39 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 11 |
| Torsemide | Torsemide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 12 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | 11 |
| Cephalexin | Cephalexin | 23 | 11 |
| Nystatin | Nystatin | 23 | 16 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Prednisone | Prednisone | 18 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Ramipril | Ramipril | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.65 · 3 records | Inspire Medical Systems, Inc. | INSPIRE, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error